Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry


ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Review Article

Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials

Author(s): Hadeer Mohamed, Mostafa Eltobgy and Omar Abdel-Rahman*

Volume 17, Issue 9, 2017

Page: [1228 - 1233] Pages: 6

DOI: 10.2174/1871520617666170102151918

Price: $65


Malignant pleural mesothelioma (MPM) is a hard to treat malignancy arising from the mesothelial surface of the pleura. Immune checkpoint inhibitors are considered a promising therapeutic strategy in many hardto- treat malignancies. In this review, we are trying to provide an in depth coverage of the prognostic value of immune checkpoints aberrations as well as discuss the different novel therapeutic strategies implementing these agents in the management of MPM.

Keywords: Mesothelioma, tremelimumab, ipilimumab, pembrolizumab, immune, prognostic value.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy